Merck Research and Development Expenses 2010-2024 | MRK

Merck annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Merck research and development expenses for the quarter ending September 30, 2024 were $5.862B, a 77.26% increase year-over-year.
  • Merck research and development expenses for the twelve months ending September 30, 2024 were $22.981B, a 6.88% decline year-over-year.
  • Merck annual research and development expenses for 2023 were $30.531B, a 125.35% increase from 2022.
  • Merck annual research and development expenses for 2022 were $13.548B, a 10.64% increase from 2021.
  • Merck annual research and development expenses for 2021 were $12.245B, a 8.6% decline from 2020.
Merck Annual Research and Development Expenses
(Millions of US $)
2023 $30,531
2022 $13,548
2021 $12,245
2020 $13,397
2019 $9,724
2018 $9,752
2017 $10,339
2016 $10,261
2015 $6,704
2014 $7,180
2013 $7,503
2012 $8,168
2011 $8,467
2010 $11,111
2009 $5,845
Merck Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $5,862
2024-06-30 $3,500
2024-03-31 $3,992
2023-12-31 $9,627
2023-09-30 $3,307
2023-06-30 $13,321
2023-03-31 $4,276
2022-12-31 $3,775
2022-09-30 $4,399
2022-06-30 $2,798
2022-03-31 $2,576
2021-12-31 $3,067
2021-09-30 $2,445
2021-06-30 $4,321
2021-03-31 $2,412
2020-12-31 $5,754
2020-09-30 $3,349
2020-06-30 $2,085
2020-03-31 $2,209
2019-12-31 $2,400
2019-09-30 $3,204
2019-06-30 $2,189
2019-03-31 $1,931
2018-12-31 $2,214
2018-09-30 $2,068
2018-06-30 $2,274
2018-03-31 $3,196
2017-12-31 $2,314
2017-09-30 $4,413
2017-06-30 $1,782
2017-03-31 $1,830
2016-12-31 $4,787
2016-09-30 $1,664
2016-06-30 $2,151
2016-03-31 $1,659
2015-12-31 $1,797
2015-09-30 $1,500
2015-06-30 $1,670
2015-03-31 $1,737
2014-12-31 $2,283
2014-09-30 $1,659
2014-06-30 $1,664
2014-03-31 $1,574
2013-12-31 $1,835
2013-09-30 $1,660
2013-06-30 $2,101
2013-03-31 $1,907
2012-12-31 $2,223
2012-09-30 $1,918
2012-06-30 $2,165
2012-03-31 $1,862
2011-12-31 $2,419
2011-09-30 $1,954
2011-06-30 $1,936
2011-03-31 $2,158
2010-12-31 $4,559
2010-09-30 $2,322
2010-06-30 $2,179
2010-03-31 $2,051
2009-12-31 $1,972
2009-09-30 $1,254
2009-06-30 $1,395
2009-03-31 $1,224
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.211B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94